{"groups":[{"description":"Velcade (bortezomib) 1.3 milligram/meter per square (mg/m\\^2) by rapid (bolus) intravenous (IV) administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.","id":"FG000","title":"Velcade (Bortezomib) Monotherapy"},{"description":"Velcade (bortezomib) 1.3 mg/m\\^2 by rapid (bolus) IV administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m\\^2 by IV infusion will be given on Day 4 of every 21-day cycle after the administration of VELCADE (bortezomib) up to 8 cycles.","id":"FG001","title":"Doxil/Caelyx Plus Velcade (Bortezomib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"37"}],"type":"Study closed by sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"257"},{"groupId":"FG001","numSubjects":"253"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"13"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"21"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"322"},{"groupId":"FG001","numSubjects":"324"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"322"},{"groupId":"FG001","numSubjects":"324"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}